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INTRODUCTION
In the past decade, vocal fold injection (VFI) has re-emerged as 
a valuable treatment modality for a variety of laryngeal disor-
ders. Recent advances in injection materials have broadened the 
indications for this technique, while the increasing capabilities of 
endoscopic technology have increased the number of available 
approaches and precision of injection delivery. The basic indica-
tions for VFI have expanded to include treatment for vocal fold 
paralysis, paresis, atrophy, and scar or sulcus (1). However, the 
myriad of options in patient selection, injectable materials, and 
approach to injection has made utilizing this modality increas-
ingly complex for the clinician.
  In the broadest sense, VFI can include procedures that target 
the superficial (subepithelial space) aspect of the vocal fold. This 
procedure involves injection of a substance as a lamina propria 
replacement. Useful for mild-to-moderate vocal fold scar and 
lamina propria defects, superficial injection provides correction 
of vibratory defects rather than global augmentation. 
  In the stricter sense, VFI refers to deep or lateral injection, as 
a means for vocal fold augmentation. Typically, deep injection 
allows for placement of a filler substance in the lateral aspect of 
the thyroartyenoid/lateral cricoarytenoid muscle complex (me-
dial aspect of the paraglottic space). The result is a medially dis-
placed free edge of the vocal fold, akin to laryngeal framework 
surgery, or type I thyroplasty. The procedure allows for correc-
tion of glottal insufficiency from a variety of causes, and is typi-
cally used to treat temporary or permanent mild-to-moderate 
glottal insufficiency (<1 to 3 mm glottal gaps). For the purposes 
of this review, VFI will refer to this latter method of deep vocal 
fold injection augmentation.
INJECTION APPROACHES
Several approaches exist to perform vocal fold injection aug-
mentation. With advancing technology, such as distal chip and 
flexible working channel laryngoscopes, awake in-office tech-
niques have become viable alternatives to the traditional micro-
suspension laryngsocopy technique. Available technology, choice 
of materials, surgeon preference, and patient preference must all 
dictate the approach used for VFI.
  Direct laryngoscopy provides the most direct approach to VFI. 
Traditionally, microscopic suspension laryngoscopy is performed 
under general anesthesia with a small endotracheal tube or un-
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der jet ventilation, and with an adequately sized laryngoscope 
in suspension. The degree of glottic incompetence is assessed 
through a combination of pre-operative awake stroboscopy and 
intra-operative visualization with microlaryngoscopy and zero-, 
thirty-, and seventy-degree angled telescopes. As an alternative, 
VFI may be done with a combination of conscious sedation and 
topical anesthesia, without endotracheal intubation, using a 
smaller slotted laryngoscope with 0-degree telescopic visualiza-
tion endoscopic vocal fold injection (2). Both techniques pro-
vide direct access to the vocal fold, and allow for precise needle 
placement along the superior arcuate line with a direct, linear 
trajectory. Additionally, both provide the ability to directly mon-
itor augmentation. These techniques prove especially valuable in 
the patient who is otherwise unable to tolerate an awake proce-
dure. However, both techniques do not provide real time assess-
ment of vocal fold closure or voice quality.
  Though VFI in the awake patient was initially described over a 
century ago, VFI in an in-office setting has re-emerged in the 
past decade as an attractive alternative to microsuspension la-
ryngoscopy. Pointing to the popularity of this technique, a recent 
multi-institutional review revealed that VFI was performed 
equally often in an awake patient as one under general anesthe-
sia (3). VFI in the awake setting has the distinct advantages of 
providing direct feedback of vocal fold closure and voice out-
come during the injection, avoiding limitations of difficult expo-
sure, and avoiding general anesthesia with its inherent risks and 
increased cost (4). Technical successes, as well as voice out-
comes, as measured by standardized patient-based voice sur-
veys, are similar to injection performed under general anesthe-
sia when performed by an experienced laryngologist (4, 5). Pa-
tient selection is critical when choosing VFI in an awake patient; 
a cooperative, calm patient without a strong gag reflex is re-
quired for successful completion. One concern about awake VFI 
lies in the relative decrease in needle control, leading to de-
crease in precision of injection. In fact, there is some evidence 
that minor complications are slightly increased in an in-office 
setting (5). In-office VFI encompasses percutaneous (trans-crico-
thryoid membrane, trans-thyroid cartilage, and trans-thyrohyoid 
membrane), per-oral, and trans-nasal endoscopic approaches. 
Typically the three approaches are performed with a flexible la-
ryngoscope in place, visualizing the larynx for visualization and 
to monitor injection effects. In most cases, optimal visualization 
is provided with a distal chip laryngoscope with digital, high 
quality video image output.
  The trans-cricothyroid membrane approach typically utilizes a 
submucosal path; a 25 g needle bent 45-degrees is inserted be-
low the inferior border of the thyroid cartilage, 3-7 mm lateral 
to midline and subsequently passed cephalad and laterally. Ap-
plying gentle pressure medially transmits motion to the vocal 
fold, allows the surgeon to confirm submusocal location of the 
needle and thus prevents perforation of the mucosa by the nee-
dle. Alternatively, with adequate tracheal anesthesia, the needle 
can be inserted into the midline in the infra-glottis, and then di-
rected superior and lateral, intraluminally, to the deep aspect of 
the vocal fold. Anatomic studies using multidetector array com-
puted tomography has confirmed this approximate 45-degree 
cephalad angle from a typical injection point 7 mm off of the 
midline (6).  
  The trans-thyroid cartilage approach utilizes a percutaneous 
approach perpendicular to the thyroid cartilage ala. A 24- or 25 
gauge needle is inserted 3 mm to 5 mm above the lower border 
of the thyroid cartilage and passed gently through the cartilage. 
Advancing the needle toward midline with gentle pressure 
transmits motion to the vocal fold, and allows the surgeon to es-
timate the location of the needle tip. Inadvertent mucosal viola-
tion may occur secondary to excessive medial pressure. Occa-
sional obstruction of the needle with cartilage may be overcome 
through pressure on the plunger, with care to avoid excessive 
pressure and possible overinjection of material. This technique is 
optimal for younger patients without extensively calcified carti-
lage. A trochar-based injection devise has been made to assist 
tran-thyroid cartilage VFI (Casiano Needle, Medtronic Inc., Jack-
sonville, FL, USA).
  The trans-thyrohyoid membrane approach utilizes an extra-
mucosal route to the vocal fold. A straight 25-gauge needle is in-
serted into the skin overlying the thyroid cartilage notch. Once 
through the thyrohyoid membrane, the needle is directed sharp-
ly caudal and advanced; with this maneuver, the needle can be 
visualized entering the lumen at the petiole of the epiglottis. 
From this position, with direct visualization using the flexible la-
ryngoscope, the needle can be directed toward the vocal fold for 
injection. Bending the needle, while improving the inferior an-
gle, often makes directing the needle more difficult, and there-
fore is discouraged. Among the percutaneous techniques, the 
trans-thyrohyoid membrane approach offers the distinct advan-
tage of direct needle placement, increasing precision of the in-
jection (7, 8).
  The per-oral vocal fold injection approach utilizes a direct ap-
proach and offers excellent precision and needle visualization. 
Topical anesthesia of the oropharynx and larynx is critical, as 
the needle is guided from the mouth to the vocal fold with a 
per-oral approach. Typically the patient is placed in a seated 
“sniffing position”, with the neck flexed and the head slightly 
extended. A flexible laryngoscope is inserted through the nose 
while the patient protrudes and holds his or her own tongue. 
Topical anesthesia may be given via an Abrahms cannula passed 
per-oral to the base of tongue, epiglottis, and true vocal folds. 
Alternatively, topical anesthetic may be applied through a flexi-
ble catheter directed through the working channel of a flexible 
laryngoscope; the laryngoscope is used to drip anesthetic onto 
the base of tongue, epiglottis, and, while the patient is phonat-
ing, onto the true vocal folds. The route of the needle is typically 
a 90-degree path, though this varies from patient to patient, and 
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passage. Typically, the false vocal fold will be retracted with the 
shaft of the needle, allowing for a lateral injection. Several com-
mercially available needles, length 220 mm to 250 mm, may be 
purchased separately or included with injectate materials for 
per-oral VFI.
  A final injection approach is the trans-nasal endoscopic ap-
proach to the vocal fold. This approach utilizes a flexible work-
ing channel laryngoscope with a 23- or 25-gauge flexible needle 
introduced through the working channel. With the needle slight-
ly from the tip of the endoscope, the needle can be guided to 
the appropriate lateral position under direct visualization. Advo-
cates describe utilizing this technique as an alternative to other 
approaches for its ease of use, patient tolerance, and ability to 
overcome anatomic and patient limitations. However, it should 
be noted that the fine gauge injection needles only accommo-
date dilute preparations of most substances unless a mechanical 
injection device is used. This approach has been advocated using 
a dilute concentration of micronized deep dermal tissue (Cyme-
tra
®), mixed with 2.3 mL of 1% lidocaine for all cases (9). It 
should also be noted that due to the length and caliber of the 
injection needle, this approach requires more than the normal 
amount of injection material to accommodate the relatively 
large dead space in the needle. 
INJECTION MATERIALS
In the past 10 years material sciences have increased the num-
ber of injectables with increased safety profile and improved 
biomechanical profiles. Materials developed have sought to 
eliminate the deleterious foreign body and inflammatory reac-
tions caused by some of the early injectable materials such as 
paraffin, silicone, and Teflon™. Recent efforts have focused on 
matching the biomechanical and viscoelastic properties of the 
superficial lamina propia. 
  Materials for deep augmentation injection are typically de-
scribed as temporary, and permanent/long lasting. Long lasting, 
and sometimes, permanent injectable materials include autolo-
gous fat, calcium hydroxylapatite (Radiesse™), polydimethylsi-
loxane (PDMS or particulate silicone), and historically, and 
polytef paste (Teflon™). Temporary injection materials include 
bovine gelatin (Gelfoam™, Surgifoam™), collagen-based prod-
ucts (Cymetra™, Zyplast™, Cosmoplast/Cosmoderm™), hyal-
uronic acid (Restylane™, Hyalaform™), and carboxymethylcel-
lulose (Radiesse Voice Gel™). The materials vary in the duration 
of integration and are thought to vary in their specific viscoelas-
tic properties and biocompatibility. 
  Autologous fat typically lasts from one to several years, and is 
considered a permanent injection by many. Though the material 
is autologous, may be generously injected, and is readily avail-
able, it is typically harvested in the operating suite under sterile 
conditions. Additionally, the survival is highly, which may be 
due to fat preparation techniques; indeed, many suggest sub-
stantial overinjection of due to this immediate variability. In ad-
dition to global augmentation, autologous lipoinjection has been 
described for vocal fold scar and vocal fold atrophy (10, 11).
  Polydimethylsiloxane, or particulate silicone, has been advo-
cated by some for global vocal fold augmentation. The duration 
of this substance is likely permanent, as alluded to in follow up 
of close to 10 years post-injection (12). Recent evidence points 
to safety and efficacy in both the short and long term, though 
complications of extrusion and foreign body reaction have been 
reported. In addition, recent studies comparing this directly to 
some of the more accepted materials do not exist (13, 14).
  Polytetrafluoroethylene, or Teflon, is another permanent in-
jectable that is of considerable historical significance but has fall-
en out of favor in the past 20 years. Long-term studies have re-
vealed significant foreign-body inflammatory reactions to this 
substance, often requiring removal with subsequent significant 
vocal fold tissue loss. Presently, Teflon it is rarely used, with 
newer substances providing safer alternatives. 
  Calcium hydroxylapatite (CaHA), known by the trade name 
Radiesse Voice, is currently a FDA approved substance for po-
tentially long-term vocal fold injection. Comprised of micro-
spheres of CaHA in a carboxymethylcellulose carrier, this sub-
stance has been studied in both animal and human studies. In 
an in vivo canine vocal fold model, it has been shown that 
CaHA injection provided adequate medialization of the canine 
vocal fold up to 12 month follow up without migration or re-
sorption, and a giant cell reaction without appreciable chronic 
inflammation (15). A recent multi-institutional clinical trial re-
vealed excellent results of 80% improvement at 12 month fol-
low-up (16). Long term clinical results show that persistent me-
dialization after CaHA injection may be present up to 2 years 
and more, with an average duration of 18 months (17).
  Bovine-based gelatin products, such as Gelfoam and Surgi-
foam, can be used for temporary vocal fold injection augmenta-
tion. An injectable version of this product may be prepared by 
mixing the powder with saline. The resulting substance is highly 
viscous, and may be used for injection by injecting with a pres-
surized syringe through a 18- or 19-gauge large bore needle. 
This has been used extensively for temporary augmentation, 
lasting 4-6 weeks and found to be very safe (18). Despite the 
excellent track record, this material has little utility due to de-
velopment of new substances that are easier to use and last lon-
ger. 
  Bovine-based collagen products, such as Zyplast, have been 
used for longer injection. There is a very small potential for al-
lergic response to this material. Thus, the FDA advocates skin 
hypersensitivity testing prior to using this substance. Despite 
this possibility, the rarity of this reaction in laryngeal injection 
augmentation has led some to question the need for testing (19). 
Atelocollagen, a water-soluble form of bovine dermal collagen, 
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scar and sulcus, though some evidence exists that this may im-
pair normal mucosal wave when injected submucosally. Bovine 
cross-linked collagen typically lasts 3 to 4 months in duration.
  Human based collagen injectables include micronized cadav-
eric dermis, such as Cymetra, and tissue engineered human col-
lagen, such as Cosmoplast/Cosmoderm. The former has been 
used extensively and results have been positive for vocal fold 
immobility and presbylarynx (20). It has also been used spar-
ingly for scar and sulcus, though this has not been studied ex-
tensively. Cymetra is clinically effective for 2 to 3 months, and 
radiographic evidence of the injectable up to 11 months has 
been reported (21). Because this is prepared from human cadav-
eric tissue, potential for infectious transmission exists, though 
this has not been documented to date. Cosmoplast/Cosmoderm 
has recent use as a dermal filler, though the experience as an 
augmentation filler for vocal folds is limited.
  Hyaluronic acid gels, such as Restylane, Hyalaform, and Juve-
derm, are animal or bacterial derived variations of the naturally 
occurring extracellular matrix glycosaminoglycan found in vari-
ous human tissues, including the vocal fold lamina propia. Clini-
cal studies have supported the safety and efficacy of this inject-
able for deep vocal fold augmentation (22, 23). Some clinical 
studies, supported by rheologic studies and animal model work 
suggest hyaluronic acid derivatives may be useful as a lamina 
propia replacement for vocal fold scar and sulcus. However, our 
clinical experience has been very disappointing and has even 
worsened vocal fold vibration when placed superficially (23-25). 
The substance is believed to last 4–6 months, though clinical ef-
fects may last up to 12 months (22, 23).
  Carboxymethylcellulose, sold as Radiesse Voice Gel, is the 
carrier substance used in the longer lasting Radiesse Voice in-
jectable. This has been utilized extensively for temporary vocal 
fold paralysis and for trial vocal fold injection augmentation for 
a variety of causes of glottic incompetence. This material re-
quires no preparation and has no biologic infection trasmission 
risk. The substance typically lasts 2-3 months after injection 
(26).
INDICATIONS
Vocal fold injection is a surgical treatment alternative to laryn-
geal framework surgery. Though each approach has advantages 
and drawbacks, no formal algorithm exists in the considerable 
circumstances where either approach may be acceptable. In gen-
eral, vocal fold augmentation is used for the temporary correc-
tion of incompetence due to unilateral vocal fold paralysis/pare-
sis, permanent correction of mild-to-moderate glottic insuffi-
ciency, and glottic insufficiency from soft tissue loss of the vocal 
fold (27).
  Temporary vocal fold injection is currently the treatment of 
choice for the treatment of glottic incompetence when prognosis 
for recovery is unclear. This is best illustrated in the case of acute 
unilateral vocal fold paralysis or paresis. During the time for po-
tential recovery of function, usually up to 6-months post-onset, 
vocal fold injection with a shorter duration substance has been 
shown to alleviate voice symptoms and improve swallowing un-
til function recovers or the patient is a candidate for a more per-
manent treatment option. In this setting, injection with collagen, 
HA, or Radiesse Voice Gel provides the best treatment option 
(20, 26, 28).
  Vocal fold injection may also be used to treat permanent 
causes of mild-to-moderate glottic insufficiency. Specifically, this 
has been successfully used to treat vocal fold atrophy, paralysis, 
paresis, and augmentation after previous framework surgery. 
Specifically, results with calcium hydroxyapatite (3, 29) and au-
tologous fat injections (30) have proven acceptable in the treat-
ment of atrophy, paralysis, and paresis. Though some have re-
ported inconsistent results with fat when compared to type I 
thyroplasty in cases of unilateral vocal fold paralysis (10), many 
may find better results with the ability to “fine tune” serial in-
jections for progressive vocal fold atrophy and presbylarynx. 
Additionally, results are promising for those requiring injection 
augmentation for recalcitrant glottic insufficiency after type I 
thyroplasty with or without arytenoid adduction (31).
  Though studies purport vocal fold injection is comparable to 
laryngeal framework surgery in many clinical scenarios, the for-
mer modality has several advantages over the latter. Patients 
with very mild forms of glottic gap (less than 1 mm) may be 
better suited for injection than framework surgery. Additionally, 
the ability to perform vocal fold injection in the awake setting 
has numerous distinct advantages over framework surgery; pa-
tient preference not to undergo an operation, and the ability to 
obtain direct voicing and vocal fold vibration feedback during 
the procedure are particularly desirable. Ease of performing the 
procedure with limited experience is greater in the case of vocal 
fold injection performed under general anesthesia, when com-
pared with laryngeal framework surgery. Finally, significant cost 
benefit has been found in the case of in-office awake injection 
when compared to those performed in the operating room (4).
  It is important to bear in mind that vocal fold injection has 
several limitations. It is generally considered feasible for a glottic 
gap up to 3 mm, after which the insufficiency becomes increas-
ingly difficult to correct. In cases of posterior glottic gap or sig-
nificantly foreshortened vocal fold, arytenoid adduction typical-
ly performed in conjunction with medialization laryngoplasty 
often provides better results. One limitation is the ability to per-
manently correct for glottic incompetence; autologous lipoinjec-
tion may be inconsistent due to the variability in viability within 
the first several weeks and calcium hydroxyapatite typically lasts 
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TIMING OF INJECTION
Currently, three clinical scenarios exist to guide the timing of 
vocal fold injection augmentation. The options for trial injection, 
temporary injection, or permanent injection should guide the 
timing and material selection for injection. Specific laryngeal pa-
thology, patient expectations, and adjunctive diagnostics will all 
aid in choosing the proper timing of injection when considering 
the type of injection performed. 
  Trial injection augmentation consists of injection of temporary 
substance in patients for whom injection benefits are unclear. In 
the case of bilateral vocal fold atrophy, voice results with injec-
tion may be unpredictable, and in these cases trial injection may 
reasonably predict the results of a more permanent augmenta-
tion (VFI or thyroplasty). In another subset, patients with dys-
phonia with a significant dysarthria component may undergo 
trial augmentation to predict if articulation difficulties do or do 
not preclude improved communication outcomes with perma-
nent augmentation. Finally, in a subset of patients, apprehension 
or unrealistic expectations exist; in these patients, trial injection 
will give an idea of realistic expectations after injection (32).
  A temporary vocal fold injection may be performed for acute 
unilateral vocal fold paralysis or paresis. In these cases of uncer-
tain recovery, laryngeal electromyogram (LEMG) may aid in de-
termining prognosis for recovery. Sensitivity for LEMG in pre-
dicting no recovery in the case of a “poor” or “fair” prognosis is 
91%. Specificity for predicting adequate recovery in the case of 
“excellent” prognosis for recovery is only 44%, however (33). 
Recent evidence suggests that the presence of laryngeal synki-
nesis can effect the prognosis for recovery. Specificity of LEMG 
with synkinesis analysis increases to 64%, while accuracy is in-
creased from 59% to 84% (34). Given this, LEMG with synki-
nesis testing can play a major role in assessing the prognosis for 
recovery.
  Permanent vocal fold injections timing varies based on specif-
ic pathology. For vocal fold paralysis, early permanent injection 
may be considered in the LEMG-determinedcase of poor prog-
nosis for recovery with or without synkinesis. Alternatively, it 
may be performed after 6-month duration in the case of persis-
tent vocal fold immobility. As discussed previously, permanent 
injection can be considered after trial injection for atrophy or 
paresis. 
FUTURE DIRECTIONS
Many advances are expected with vocal fold injection. Current-
ly, no optimal materials exist for superficial lamina propia re-
placements; injectable materials that improve or enhance muco-
sal wave would prove to be immensely useful in the treatment 
of vocal fold scar and sulcus vocalis. Improvements in the deliv-
ery methods or the viscosity of materials would allow for im-
proved injection delivery through a trans-nasal endoscopic ap-
proach. Finally, improvements in instrumentation, such as articu-
lating cannulas may aid in performing injections in the awake, 
in-office setting.
  Currently, much research concentrates on optimizing the bio-
mechanical matches of injectables with the host tissue. The thy-
roarytenoid/lateral cricoarytenoid muscle complex as well as 
the superficial lamina propria have specific rheologic properties 
affecting mucosal wave characteristics, vocal fold vibration, and 
ultimately voice quality. Studies examining the effects of injec-
tion on the viscoelastic properties of the specific host site exist. 
Future development of vocal fold injectable materials will likely 
focus on providing a product that is not only safe, but function-
ally matches host viscoelastic properties. This is important both 
in the short-term and in the long-term, where tissue incorpora-
tion may alter the typical characteristics of the material/vocal 
fold interactions.
CONCLUSION
Vocal fold injection is a proven technique with favorable results 
for the treatment of mild-to-moderate glottic insufficiency due 
to a variety of causes. The technique has the advantages of abili-
ty to perform in an in-office, awake setting and may be easier to 
master than laryngeal framework surgery. In select cases of tem-
porary paralysis or paralysis with uncertain prognosis, tempo-
rary vocal fold injection may be considered the standard of care 
for treating glottic insufficiency. Recent advances in material en-
gineering and digital imaging technology have made this an at-
tractive alternative to laryngeal framework surgery that must be 
considered in a variety of clinical scenarios.
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